Perifosine (KRX-0401)

For research use only.

Catalog No.S1037 Synonyms: NSC639966

118 publications

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 470 In stock
USD 870 In stock
USD 1970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Perifosine (KRX-0401) has been cited by 118 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  M1HDXmZ2dmO2aX;uJGF{e2G7 MmTHNE42NzFxMj61JO69VQ>? MV2zJIg> MoLqdoVlfWOnczD0bIUh[mG|YXygR2IhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXzlXlVNOjZyOUe4O|M>
T24 BC  M2fweWNmdGxiVnnhZoltcXS7IFHzd4F6 M{LE[VAvPS9zL{KuOUDPxE1? NF;OW4czPCCq NGLOdXpmdmijbnPld{B{d3KjZnXubYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDk[YNz\WG|ZR?= M{HuNlI3ODl5OEez
T24 BC  NF[4UI5CeG:ydH;zbZMhSXO|c3H5 NVT1ZXQ2Oi53IN88US=> NVfHVXZrOjRiaB?= NYjk[Ydpe2Wwc3n0bZpmeyCEQzDj[YxteyC2bzDzc5Ji\mWwaXKtbY5lfWOnZDDhdI9xfG:2aXRCpC=> M3zsRVI3ODl5OEez
HepG2 NH3qcYNHfW6ldHnvckBCe3OjeR?= NGPrWIUzOMLizszN NUfsdmhFOjUEoHi= MnPBdJJw\HWlZYOgZY4hcW62ZX7z[UBkgXSxcHzhd41q[yC4YXP1c4xqgmG2aX;uJINwenKnc4DvcoRqdmdidH:gZUBvd3SjYnzlJIRqdGG2YYTpc44hd2ZidHjlJGVTKGOrc4Tldo5{ MVKyOVk{PDJ|Mh?=
U-87 MG  M4[xdGZ2dmO2aX;uJGF{e2G7 Ml3WNlDDqM7:TR?= NX3JSW85OjUEoHi= MkPXbY5kemWjc3XzJIRwfWKuZT3t[Y1jemGwZTDic5Vv\CC|dIL1Z5R2emW| MYCyOVk{PDJ|Mh?=
HepG2 MU\GeY5kfGmxbjDBd5NigQ>? MX:yNOKh|ryP NG\iXGU3NzJ2IHi= Mme3bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS MknjNlU6OzR{M{K=
U-87 MG  NV3PenJ{TnWwY4Tpc44hSXO|YYm= M1\WbVIxyqEQvF2= MWe2M|I1KGh? Mnj5bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS MkL5NlU6OzR{M{K=
HepG2 NX61WXBUTnWwY4Tpc44hSXO|YYm= MVGyNOKh|ryP NGDqN|U3NzJ2IHi= NHPMfHll\WO{ZXHz[ZMhVEN|LVnJJIRm\3KjZHH0bY9vyqCocn;tJFYhcA>? MWKyOVk{PDJ|Mh?=
U-87 MG  MkfTSpVv[3Srb36gRZN{[Xl? M4\NR|IxyqEQvF2= Moq5Ok8zPCCq NGfjTGZqdmO{ZXHz[ZMhfGinIHH1eI9xcGGpaXOg[ox2gCBiYYSgOkBpKHeqaXzlJIlvcGmkaYTzJJRpcXNiZnz1fEBifCB{NHi= MoG4NlU6OzR{M{K=
HepG2 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:4cI8zOC92MDFOwG0> MYWyOE81QCCq M3ziXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVHaR4JDOjV7M{SyN|I>
U-87 MG  M{DaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmyNE81OCEQvF2= NHuyZ|MzPC92ODDo MlrobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEP2c2EzPTl|NEKzNi=>
A549 NISxPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml64NE4{NTFyIN88US=> NITQVWozPC95MjDo MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlrGNlU3QTd6OUm=
H460 NYfIcFNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PYOFAvOy1zMDFOwG0> NVeydINvOjRxN{KgbC=> MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoDlNlU3QTd6OUm=
A549 M3XIVmFxd3C2b4Ppd{BCe3O|YYm= NWXhc4pSOS9|IN88US=> NVnzRol7PDhiaB?= M1fRZYlv\HWlZYOgZZBweHSxc3nz Mn3zNlU3QTd6OUm=
H460 NYnyW2JXSXCxcITvd4l{KEG|c4PhfS=> MYexM|Mh|ryP MonVOFghcA>? NHz4dpBqdmS3Y3XzJIFxd3C2b4Ppdy=> M4nGXlI2Pjl5OEm5
A549 MVnGeY5kfGmxbjDBd5NigQ>? NVKwdFF{OyEQvF2= NFfQfGI5KGh? MnvQZoxw[2u|IFHLWEBi[3SrdnH0bY9v NF\MR5gzPTZ7N{i5PS=>
H460 NF7UcY1HfW6ldHnvckBCe3OjeR?= NEj3XoY{KM7:TR?= NFzSfVg5KGh? MmrOZoxw[2u|IFHLWEBi[3SrdnH0bY9v NFjtZm4zPTZ7N{i5PS=>
A549 M1Kyb2Z2dmO2aX;uJGF{e2G7 MYqzJO69VQ>? NYf2OWY3QCCq M3vmfoJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= NInNNHozPTZ7N{i5PS=>
H460 M3TJRmZ2dmO2aX;uJGF{e2G7 NUXt[FBzOyEQvF2= NFr1NnU5KGh? NI\4UZhjdG:la4OgcXRQWkNzLDDhcoQhTVKNLV3BVGsh[WO2aY\heIlwdiClb33ibY5m\CC5aYToJG1GUy1zNkK= MnjhNlU3QTd6OUm=
RMG1 M1fHe2NmdGxiVnnhZoltcXS7IFHzd4F6 MVSxMVMxKM7:TR?= NWn1e2VXPzJiaB?= MkTT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{DJU|I2PTF7MUS4
RMG2 NX\ES4VES2WubDDWbYFjcWyrdImgRZN{[Xl? NFTofpcyNTNyIN88US=> Ml7aO|IhcA>? NYLQfpJC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MYOyOVUyQTF2OB?=
KOC7C M3rQSGNmdGxiVnnhZoltcXS7IFHzd4F6 NFfyUJcyNTNyIN88US=> NVWz[YN7PzJiaB?= M13weoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MX[yOVUyQTF2OB?=
HAC2 NEfvZ2tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkW1NU0{OCEQvF2= M{LaVFczKGh? NH7QWI5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M{T5blI2PTF7MUS4
RMG2 NWXoepZoS2WubDDWbYFjcWyrdImgRZN{[Xl? MkDMNU0{OCEQvF2= MnvKOFghcA>? NG\2RpFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NWfXWW17OjV3MUmxOFg>
OVISE MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWqxMVMxKM7:TR?= M2K3d|Q5KGh? M3jrUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MmfnNlU2OTlzNEi=
SKOV3 Mlf3R4VtdCCYaXHibYxqfHliQYPzZZk> MnnvNU0{OCEQvF2= MWC0PEBp MVvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXLPeXRpOjV3MUmxOFg>
A2780 Mn30R4VtdCCYaXHibYxqfHliQYPzZZk> NHPXfXgyNTNyIN88US=> MWS0PEBp NEjrepll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NVHXcGs6OjV3MUmxOFg>
RMG1 MVTBdI9xfG:|aYOgRZN{e2G7 NGeyUZQ{OCEQvF2= Ml20NlQhcA>? NGHHUZJqdmS3Y3XzJIFxd3C2b4Ppdy=> M4GxUFI2PTF7MUS4
RMG2 M3X1fmFxd3C2b4Ppd{BCe3O|YYm= M1XtZ|MxKM7:TR?= NFv1b4EzPCCq M3fkUolv\HWlZYOgZZBweHSxc3nz MkHoNlU2OTlzNEi=
HCC1806 NVXlUWl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMVExKM7:TR?= NGfsVnc1QCCq NVPEfndzTUN3ME2yMlg16oDLwsJihKkxNjB5IN88US=> MmrPNlUzQTN3N{[=
MDA-MB-231  NFy3UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCwMVExKM7:TR?= NYm2TI9UPDhiaB?= MmS1SWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?= M1v1RlI2Ojl|NUe2
GL-1 NIDjPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:2VlAvOeLCk{GwNQKBkc7:TR?= MlLaOFghcA>? MnewTWM2OD17LkmxJO69VQ>? NYHUNGo4OjR6OEG1NFg>
CLBL-1 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW5TGkxNjIkgKOxNFDjiIoQvF2= MUO0PEBp M3S2SWlEPTB;M{OuNEDPxE1? MWWyOFg5OTVyOB?=
UL-1 NEi5[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi3NE4y6oDVMUCw5qCK|ryP NWnJflZkPDhiaB?= NUfJUnpQUUN3ME23MlAyKM7:TR?= MmHlNlQ5QDF3MEi=
Ema M2PSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPyflF{OC5z4pETNVAx6oDLzszN M3\idVQ5KGh? NIrLVmtKSzVyPUW4Mlch|ryP MX6yOFg5OTVyOB?=
PANC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ic5IxNTJ3IN88US=> MVq3NkBp MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M17B[lI1PTF7N{Wx
MIA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSwMVI2KM7:TR?= MY[3NkBp NWDtdoo6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkjuNlQ2OTl5NUG=
AsPC-1 NXXmXpoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTlNE0zPSEQvF2= NW\wS5lvPzJiaB?= MnzpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MX2yOFUyQTd3MR?=
PANC-1 MX\GeY5kfGmxbjDBd5NigQ>? NGfhepgxNjVizszN NGPkNnEzPCCq MljtbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh MYiyOFUyQTd3MR?=
MIA MmfDSpVv[3Srb36gRZN{[Xl? Mn;YNE42KM7:TR?= NEnUN4UzPCCq MlvRbY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh MkjrNlQ2OTl5NUG=
AsPC-1 NYTTepF2TnWwY4Tpc44hSXO|YYm= NXTqTHd1OC53IN88US=> MYWyOEBp M3TWfYlvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb|EwOiCyaH;zdIhwenmuYYTpc47DqA>? NIXqVJkzPDVzOUe1NS=>
U87MG MnXkR4VtdCCYaXHibYxqfHliQYPzZZk> NV3iXZhbOC1{NTFOwG0> M2DxWVI1NTl4IHi= Mm[y[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy Ml\UNlQxPjV3MkK=
SGC7901  NULDdFd6TnWwY4Tpc44hSXO|YYm= NFHqVWIxNjd3L{GwxsDPxE1? NWXS[FJvPDhiaB?= NEn0Wopl\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA> MWiyN|kyOjJ2Nh?=
MGC803  MoLUSpVv[3Srb36gRZN{[Xl? NWLGOWx3OC55NT:xNOKh|ryP NWGwTFdDPDkEoHi= NU\nb|Nj\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh NVGxT|htOjN7MUKyOFY>
TykNu NUX0[Zo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS0cmtKSzVyPUOuOUDPxE1? MV[yN|g4PzBzMh?=
TykNuR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f5VGlEPTB;NT61JO69VQ>? MoD5NlM5PzdyMUK=
M41 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHaTWM2OD1{ND63JO69VQ>? NYX1[oZUOjN6N{ewNVI>
M41R NX;qVVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3EUHllUUN3ME2xPU45KM7:TR?= NFnNWpozOzh5N{CxNi=>
OVCAR8 M3XYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNzLkGg{txO M375RVI{QDd5MEGy
HeyA8 NIXBT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH2VHYyUUN3ME2yOE4{KM7:TR?= NI\1elczOzh5N{CxNi=>
A2780CP NGT2Om1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm1d5Q3UUN3ME23MlYh|ryP MlG4NlM5PzdyMUK=
OVCAR5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLNTWM2OD14Lkeg{txO NHrXXXQzOzh5N{CxNi=>
A2780S MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD1zND61JO69VQ>? MVmyN|g4PzBzMh?=
MCAS M3\NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPrd5VKSzVyPUGyMlUh|ryP M2HX[VI{QDd5MEGy
NCI-H727 NYDzOFhIS2WubDDWbYFjcWyrdImgRZN{[Xl? MoDBNE0yODBizszN NV3YUmR1OjRxN{KgbC=> NFLMRlNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MlfyNlI1QTl2M{e=
GOT1 NXrt[2JkS2WubDDWbYFjcWyrdImgRZN{[Xl? MXOwMVExOCEQvF2= NFjuOGgzPC95MjDo MojK[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NXjEOppGOjJ2OUm0N|c>
BON1 NHvCWmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXPL[pZYOC1zMECg{txO M3S3eFI1Nzd{IHi= MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NGCyNZQzOjR7OUSzOy=>
BON1 MonWRZBweHSxc3nzJGF{e3OjeR?= MV2wMVExKM7:TR?= MljmNlQhcA>? MUDpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 M4C0R|IzPDl7NEO3
BON1 NV;QfJliTnWwY4Tpc44hSXO|YYm= NULjVVVZPy53L{GwJO69VQ>? Ml30PEBp MVTk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[geIhmKGGwdHmtZZBweHSxdHnjJJBzd3SnaX7zJGJEVDJiYX7kJGJkdC2[TB?= M{DwdFIzPDl7NEO3
Kasumi-1 NFrjWJNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX\jTo5POC1{MDFOwG0> MYOyOE81QCCq NHHHXnNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NHLwfoMzOjRyN{KyPC=>
HL-60 NVzvRpRwS2WubDDWbYFjcWyrdImgRZN{[Xl? MnX1NE0zOCEQvF2= NHfVe3UzPC92ODDo M2HubIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MXSyNlQxPzJ{OB?=
Kasumi-1 MkC2RZBweHSxc3nzJGF{e3OjeR?= NF7hdmIyOCEQvF2= MXeyOEBp NED4S3BqdmS3Y3XzJIFxd3C2b4Ppdy=> NFnmem0zOjRyN{KyPC=>
HL-60 MofuRZBweHSxc3nzJGF{e3OjeR?= NEPoVJUyOCEQvF2= MVOyOEBp NU\rWXN2cW6mdXPld{BieG:ydH;zbZM> MXeyNlQxPzJ{OB?=
Kasumi-1 M2m3R2Z2dmO2aX;uJGF{e2G7 NHLQOYozNjVxNT:xNEDPxE1? NXHTdWx1OjRiaB?= M2r3T4Rm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? NXe2OFdHOjJ2MEeyNlg>
HL-60 NWLKN4xXTnWwY4Tpc44hSXO|YYm= NF\Sd3UzNjVxNT:xNEDPxE1? NIjkXIQzPCCq MorD[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6 M{TBRlIzPDB5MkK4
Kasumi-1 NHfISVVHfW6ldHnvckBCe3OjeR?= NYrJV412Oi53L{WvNVAh|ryP MVqyOEBp M3;5XYlv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkXuNlI1ODd{Mki=
HL-60 NXv4UY0zTnWwY4Tpc44hSXO|YYm= NXXFT2dROi53L{WvNVAh|ryP MUeyOEBp Ml3RbY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M{XvcVIzPDB5MkK4
K562 NYfrZVdmTnWwY4Tpc44hSXO|YYm= MXiyNEDPxE1? NILOZZE1QCCq NUfWcnRMcW6mdXPld{BifXSxcHjh[5nDqA>? M2rqN|IzPDB5MkK4
OCUT1 M3XHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrBNE4yNTNizszN MlLxOUBl Mn;UbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3zaNFIzODlyMkex
K1 M3S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrrNE4yNTNizszN NVTqenY6PSCm NVrSbHV7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MYCyNlA6ODJ5MR?=
OCUT1 MVnGeY5kfGmxbjDBd5NigQ>? M3;od|Mh|ryv NGHB[ZUzPCCq MV;jZZV{\XNiYTDkdoFu[XSrYzDpcoNz\WG|ZTDpckBIOi:PIIDoZZNm MmTTNlIxQTB{N{G=
CaOV3 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mk\0NU82NzFyIN88US=> M{HNV|Q5KGh? M{nNeIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6ncjDjc5Rz\WG2ZXSge4l1cCCyYXPsbZRigGWu M{O3VVIyPzd3MEW0
SKOV3 NYPQeFVsS3m2b4TvfIlkcXS7IFHzd4F6 NHSwcWE2KM7:TR?= NHT1dpk1QCCq M3TUfYVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NYDHfZRPOjF5N{WwOVQ>
A2780 M2LN[2N6fG:2b4jpZ4l1gSCDc4PhfS=> MXS1JO69VQ>? M1fSNFQ5KGh? NVTnSHV{\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? MV6yNVc4PTB3NB?=
HT-29  M3TEXWN6fG:2b4jpZ4l1gSCDc4PhfS=> MoOyOUDPxE1? MWq0PEBp NIXITJZmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh MUiyNVc4PTB3NB?=
A498 NIjrT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnJO4ExNTRyIN88US=> M1W0TlczKGh? NUCyTGM4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFHESlEzOTZ2NEC1NC=>
CAKI-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LkbFAuPDBizszN M3q5cVczKGh? MoLtTWM2OH5zMDFOwG0> M{\kUVIyPjR2MEWw
769-P NVHLb5lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMVQxKM7:TR?= NH7IOpg4OiCq NFjkR4RKSzVyfkWtNVAh|ryP MYWyNVY1PDB3MB?=
786-0 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrlNE01OCEQvF2= NVq5[5ZRPzJiaB?= MUXJR|UxhjVizszN MUCyNVY1PDB3MB?=
786-O NIPjdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmwMVIxKM7:TR?= M2D0SlczKGh? NUDzcllrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlXtNlE3PDRyNUC=
CAKI-1 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nheVAuOjBizszN NFX3WoU4OiCq NX;GOJpxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mn;hNlE3PDRyNUC=
769-P NV64[HV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LXXlAuOjBizszN MXW3NkBp MmjtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mmm2NlE3PDRyNUC=
A498 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HKTVAuOjBizszN NYO2XZhZPzJiaB?= M{C5e4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXWyNVY1PDB3MB?=
CWR22RV1 NEPaelRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{fxc|ExKM7:TR?= NI\rNGkzPCCq NHTsVJJqdmO{ZXHz[ZMhe2Wwc3n0bZZqfHlib3[gbJVu[W5iQ2fSNlJTXjFiY3XscJMhfG9icnHkbYF1cW:w MojjNlE1QTZ{N{O=
CWR22RV1 NWf6TXRbSXCxcITvd4l{KEG|c4PhfS=> M3uyVlExKM7:TR?= MkjBNlQhcA>? MXPlcohidmOnczDyZYRq[XSrb36gbY5lfWOnZDDhdI9xfG:|aYO= MY[yNVQ6PjJ5Mx?=
CWR22RV1 NHjVS|NHfW6ldHnvckBCe3OjeR?= NXfDWmJuPSEQvF2= MVmyOEBp M3\oeZJm\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGFsfCC|aXfubYZq[2GwdHz5 M2noWFIyPDl4Mkez
HepG2  NY\ENopqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO1M|ExNzJyL{SwJO69VQ>? NYXQTGF3OjRxNEivO|IhcA>? Mnv0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFTIc4szODh2MkSyOS=>
Bel-7402 M1XIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7LOU8yOC9{MD:0NEDPxE1? NEHhcYszPC92OD:3NkBp MnuxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{DxfFIxQDR{NEK1
HepG2  NVjZNpdsTnWwY4Tpc44hSXO|YYm= NFfnSJg2NzFyL{KwJO69VQ>? NWnUOZF2OjRiaB?= NXXtU4tXemW|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl NYHBZodrOjB6NEK0NlU>
Bel-7402 M{nSc2Z2dmO2aX;uJGF{e2G7 MXy1M|ExNzJyIN88US=> NFj5O5IzPCCq M{LET5Jme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG|ZR?= M3fpbFIxQDR{NEK1
HepG2  MkfLRZBweHSxc3nzJGF{e3OjeR?= NHvLOIs2NzFyL{KwJO69VQ>? NEfG[Y4zPC92ODDo NXG1SHRlcW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=> M3Oyb|IxQDR{NEK1
Bel-7402 NXr4WYdTSXCxcITvd4l{KEG|c4PhfS=> M4O0cVUwOTBxMkCg{txO NXfQbmRLOjRxNEigbC=> NG\UNoxqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl M1XsPVIxQDR{NEK1
OAW-42 NEPhXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqwMVQxKM7:TR?= M2niRVczyqCq MnjKTWM2OH5zMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFXINmkzODRyNUK5Oi=>
PA-1  Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLXO2UxNTRyIN88US=> MlixO|LDqGh? MlTtTWM2OH5{NTFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MmmxNlA1ODV{OU[=
SKOV3  NVHHRZFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX65NHR5OC12MDFOwG0> NF7Z[244OsLiaB?= NGrSco9KSzVyfkOwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MU[yNFQxPTJ7Nh?=
A2780 M3vSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HjWVAuOjBizszN M4XHWFQ5Nzd{IHi= NH3aT21KSzVywrC9xsA{yqEQvH2= M{PMXlIxPDB3Mkm2
A2780cis  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\2UJoxNTJyIN88US=> MXi0PE84OiCq NIjxc2JKSzVywrC9xsA3yqEQvH2= NYL4VGVCOjB2MEWyPVY>
SKW6.4 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:wUmY1Oi1zMNMg{txO MX60POKhcA>? NVHUSVVWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{PGZ|IxOTNyOU[w
MAVER MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvFNk0yOMLizszN MoXmOFjDqGh? M{W2PIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NIrtcG8zODF|MEm2NC=>
BJAB M{LPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL6Nk0yOMLizszN MVO0POKhcA>? NFXh[ndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MYKyNFE{ODl4MB?=
OCI MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzZN3YzNTFywrFOwG0> MmO1OFjDqGh? MlnrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MkTTNlAyOzB7NkC=
MOLM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TJZVIuOTEEoN88US=> M1y5RlQ5yqCq NU\sVmE6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWKyNFE{ODl4MB?=
HL-60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfINk0yOMLizszN M1nXTFQ5yqCq MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Mn3SNlAyOzB7NkC=
SKW6.4 NFfuc3RCeG:ydH;zbZMhSXO|c3H5 MVixNOKh|ryP NWH4[VY4OjRxNEigbC=> MkfzbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= M{i2NVIxOTNyOU[w
MAVER MWDBdI9xfG:|aYOgRZN{e2G7 MXmxNOKh|ryP NEnpO2UzPC92ODDo NFHJNJhqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MnrNNlAyOzB7NkC=
BJAB MkDYRZBweHSxc3nzJGF{e3OjeR?= NXnrW5BXOTEEoN88US=> NVX2WHZiOjRxNEigbC=> MULpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 M{nzNlIxOTNyOU[w
OCI MWTBdI9xfG:|aYOgRZN{e2G7 M3HpSFExyqEQvF2= MU[yOE81QCCq MUnpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 M4f3PVIxOTNyOU[w
MOLM NGDHR2hCeG:ydH;zbZMhSXO|c3H5 NVPh[FQxOTEEoN88US=> MVGyOE81QCCq MVzpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 MYiyNFE{ODl4MB?=
HL-60 NXy0XY9uSXCxcITvd4l{KEG|c4PhfS=> M3XmcFExyqEQvF2= NEDvfI4zPC92ODDo NXeyXpNrcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> M124O|IxOTNyOU[w

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-S6K1 / S6K1 ; 

PubMed: 25519148     


The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies.

PARP; 

PubMed: 25519148     


Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting

p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; 

PubMed: 19920197     


The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h.

p-PDK1 / p-GSK3α/β / p-S6R ; 

PubMed: 17761832     


BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies.

25519148 19920197 17761832
Growth inhibition assay
Cell viability; 

PubMed: 28332584     


Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.

28332584
In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
- Collapse

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
- Collapse
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966
Smiles CCCCCCCCCCCCCCCCCCO[P]([O-])(=O)OC1CC[N+](C)(C)CC1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01224730 Completed Drug: perifosine Cancer AEterna Zentaris January 24 2012 Phase 1
NCT01049841 Completed Drug: perifosine + temsirolimus Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01048580 Completed Drug: Perifosine|Drug: Capecitabine Colon Cancer AEterna Zentaris|SCRI Development Innovations LLC October 2009 Phase 1
NCT00776867 Completed Drug: perifosine Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin Madison|Duke University|AEterna Zentaris October 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID